Protocol Ledger

NCT06798896 · Phase II · RECRUITING

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

Interventional Phase II clinical trial protocol NCT06798896 sponsored by Supernus Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-30 Enrollment: 216 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06798896
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)216 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06798896
Protocol FieldVerified Registry Value
NCT IdentifierNCT06798896
Consolidated Lead SponsorSupernus Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment216 participants (ESTIMATED)
Registered Start Date2024-12-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06798896
Hospital Research SiteLocationSite Profile
UCI Health and Chao Family Comprehensive Cancer CenterOrange, CAOpen Hospital Dossier ->
Yale Cancer Center and Smilow Cancer HospitalNew Haven, CTOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI